Publications
On this page:
Breast Working Group
Lee SJ, Zelen M. Mortality modeling of early detection programs. Biometrics 2008;64:386-95. [Abstract]
Mandelblatt JS, Potosky AL. On the road to improving the quality of breast cancer care: a distance still to travel. Med Care 2008 Aug;46(8):759-61. [Abstract]
Mandelblatt JS, Silliman R. Hanging in the balance: making decisions about the benefits and harms of breast cancer screening among the oldest old without a safety net of scientific evidence. J Clin Oncol 2008 Dec 15.
Stout NK, Goldie SJ. Keeping down the noise: common random numbers for disease simulation modeling. Health Care Manag Sci 2008 Dec;11(4):399-406. [Abstract]
Tosteson ANA, Stout NK, Fryback DG, Acharyya S, Herman B, Hannah H, Pisano E. Cost-effectiveness of digital mammography breast cancer screening: results from ACRIN DMIST. Ann Intern Med 2008;148(1):1-10. [Abstract]
Hanin LG, Yakovlev A. Identifiability of the joint distribution of age and tumor size at detection in the presence of screening. Math Biosci 2007 Aug;208(2):644-57. [Abstract]
Plevritis SK, Salzman P, Sigal BM, Glynn PW. A natural history model of stage progression applied to breast cancer. Stat Med 2007 Feb 10;26(3):581-95. [Abstract]
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-74. [Abstract]
Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006;36:1-126.
Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monographs 2006;(36):1-2. [Extract]
Feuer EJ. Chapter 1: Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem. J Natl Cancer Inst Monographs 2006;(36):2-6. [Extract]
Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Chapter 2: Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monographs 2006;(36):7-15. [Abstract]
Rosenberg MA. Chapter 3: Competing risks to breast cancer mortality. J Natl Cancer Inst Monographs 2006;(36):15-9. [Abstract]
Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Chapter 4: Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monographs 2006;(36):19-25. [Abstract]
Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Chapter 5: Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monographs 2006;(36):26-9. [Abstract]
Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Chapter 6: Modeling the impact of treatment and screening on U.S. breast cancer mortality: a bayesian approach J Natl Cancer Inst Monographs 2006;(36):30-6. [Abstract]
Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. Chapter 7: The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monographs 2006;(36):37-47. [Abstract]
Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. Chapter 8: The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monographs 2006;(36):47-55. [Abstract]
Tan SYGL, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer. J Natl Cancer Inst Monographs 2006;(36):56-65. [Abstract]
Hanin LG, Miller A, Zorin AV, Yakovlev AY. Chapter 10: The University of Rochester Model of Breast Cancer Detection and Survival. J Natl Cancer Inst Monographs 2006;(36):66-78. [Abstract]
Lee S, Zelen M. Chapter 11: A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monographs 2006;(36):79-86. [Abstract]
Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P.Chapter 12: A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monographs 2006;(36):86-95. [Abstract]
Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ. Chapter 13: A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monographs 2006;(36):96-105. [Abstract]
Habbema JD, Tan SYGL, Cronin KA. Chapter 14: Impact of mammography on U.S. breast cancer mortality, 1975–2000: are intermediate outcome measures informative?J Natl Cancer Inst Monographs 2006;(36):105-11. [Abstract]
Cronin KA, Feuer EJ, Clarke LD, Plevritis SK.Chapter 15: Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst Monographs 2006;(36):112-21. [Abstract]
Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ. Chapter 16: Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience. J Natl Cancer Inst Monographs 2006;(36):122-26. [Abstract]
Hanin LG, Pavlova LV. Optimal regimens of cancer screening. In: Edler L, Kitsos CP, eds. Recent advances in quantitative methods in cancer and human health risk assessment. New York: Wiley; 2006. Jun p. 177-91. [Summary]
Liang W, Kasman D, Wang JH, Yuan EH, Mandelblatt JS. Communication between older women and physicians: preliminary implications for satisfaction and intention to have mammography. Patient Educ Couns 2006 Dec;64(1-3):387-92. [Abstract]
Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006 May 24;295(20):2374-84. [Abstract]
Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006;98(11):774-782. [Abstract]
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habberna JDF, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. New Eng J Med 2005 Oct 27;353(17):12-20. [Abstract]
Cronin KA,Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, Ballard-Barbash R, Geller BM, Feuer EJ. Modeling the dissemination of mammography in the United States. Cancer Causes Control 2005;16:701-712. [Abstract]
Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Extermann M, Fox S, Orosz G, Silliman R, Cullen J, Balducci L. Breast Cancer In Older Women Research Consortium. Toward optimal screening strategies for older women. J Gen Intern Med 2005 Jun;20(6):487-96. [Abstract]
Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann Intern Med 2005 Jun 21;142(12 Pt 2):1073-9. [Abstract]
Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat 2005 Jan;89(1):47-54. [Abstract]
Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005 Aug 17;97(16):1195-203. [Abstract]
Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostat 2005;6(4):604-14. [Abstract]
Zelen M. Risks of cancer and families. J Natl Cancer Inst 2005 Nov 2;97(21):1556-7. [Abstract]
Zorin AV, Edler L, Hanin LG, Yakovlev AY. Estimating the natural history of breast cancer from bivariate data on age and tumor size at diagnosis. In: Edle L, Kitsos CP, editors. Recent Advances in Quantitative Methods for Cancer and Human Health Risk Assessment. New York: Wiley; 2005. p. 317-27. [Summary]
Andersen LD, Remington PL, Trentham-Dietz A, Robert S. Community trends in the early detection of breast cancer in Wisconsin, 1980-1998. Am J Prev Med 2004 JAn;26(1):51-5. [Abstract]
Boer R, Plevritis S, Clarke L. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Methods Med Res 2004 Dec;13(6):525-38. [Abstract]
Boucher KM, Asselain B, Tsodikov AD, Yakovlev AY. Semiparametric versus parametric regression analysis based on the bounded cumulative hazard model: An application to breast cancer recurrence. In: Nikulin MS, Balakrishnan N, Mesban M, Limnios N, eds. Parametric and Semiparametric Models with Applications to Reliability, Survival Analysis, and Quality of Life. Boston, MA: Birhauser; 2004. p. 399-418.
Chia L, Salzman P, Plevritis SK, Glynn PW. Simulation-based parameter estimation for complex models: a breast cancer natural history modeling illustration. Stat Methods Med Res 2004 Dec;13(6):507-24. [Abstract]
Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostat 2004;5(4):603-13. [Abstract]
Hanin LG, Yakovlev AY. Multivariate distributions of clinical covariates at the time of cancer detection. Stat Methods Med Res 2004 Dec;13(6):457-89. [Abstract]
Hu P, Zelen M. Planning of randomized early detection trials. Stat Methods Med Res 2004;13:491-506. [Abstract]
Lee S, Huang H, Zelen M. Early detection of disease and the scheduling of examinations. Stat Methods Med Res 2004;13:443-56. [Abstract]
Mandelblatt J, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Muennig P. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004 Jul 1;22(13):2554-66. [Abstract]
Zelen M. Forward and backward recurrence times and length biased sampling: Age specific models. Lifetime Data Anal 2004;10:325-34. [Abstract]
Davidov O, Zelen M. The theory of case-control studies for early detection programs. Biostat 2003;4:411-21. [Abstract]
Lee SJ, Zelen M. Modeling the early detection of breast cancer. Ann Oncol 2003;14:1199-202. [Abstract]
Mandelblatt J, Saha S, Teutsch S. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2003 Nov 18;139(10):835-42. [Abstract]
Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, Hadley J, Schulman KA. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol 15 Mar 2003;21(6):1139-46. [Abstract]
Stout NK, Rosenberg MA, Fryback DG. Does diagnosis by screening mammography lead to a gain in life expectancy for women with breast cancer and if so how much? Med Decis Making 2003;23(6):552.
Stout NK, Rosenberg MA, Remington PL, Trentham-Dietz A, Fryback DG. Can routine screening really reduce breast cancer mortality by 40-60%. Med Decis Making 2003;23(6):559.
Tan SYGL, van Oortmarssen GJ, Piersma N. Estimating parameters of a microsimulation model for breast cancer screening using the score function method. Ann Oper Res 2003;119:43-61. [Abstract]
Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J. Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev 2003 Sep;60(3):294-331. [Abstract]
Hanin L. Identification problem for stochastic models with application to carcinogenesis, cancer detection and radiation biology. Discrete Dyn Nat Soc 2002;7:177-89. [Absract]
Hu P, Zelen M. Experimental design issues for the early detection of disease: novel designs. Biostat 2002;3(3):299-313. [Abstract]
Lee SJ, Zelen M. Statistical models for screening: planning public health programs. Cancer Treat Res 2002;113:19-36. [Abstract]
Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002 Nov 6;94(21):1626-34. [Abstract]
Parmigiani G, Skates S, Zelen M. Modeling and optimization in early detection programs with a single exam. Biometrics 2002;58:30-6. [Abstract]
Zelen M, Lee SJ. Models and the early detection of disease: methodological considerations. Cancer Treat Res 2002;113:1-18. [Abstract]
Bartoszynski R, Edler L, Hanin L, Kopp-Schneider A, Pavlova L, Tsodikov A, Zorin A, Yakovlev AY. Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci 2001 Jun;171(2):113-42. [Abstract]
Hanin, LG; Tsodikov, AD; Yakovlev, AY. Optimal schedules of cancer surveillance and tumor size at detection. Math Comp Modell. 2001;33(12):1419-30. [Abstract]
Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS; Cost Work Group, Third U.S. Preventive Services Task Force. The art and science of incorporating cost-effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001 Apr;20(3 Suppl):36-43. [Abstract]
Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics 2001 Dec;57(4):1009-17. [Abstract]
Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001 Aug 1;19(15):3490-9. [Abstract]
Yabroff KR, O'Malley A, Mangan P, Mandelblatt J. Inreach and outreach interventions to improve mammography use. J Am Med Womens Assoc 2001;56(4):166-73, 188. [Abstract]
Colorectal Working Group
Bentley TG, Willett WC, Weinstein MC, Kuntz KM. The effects of categorizing continuous variables in decision-analytic models. Med Decis Making In Press.
Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, Habbema JDF. Individualizing colonoscopy screening by gender and race. Gastrointest Endosc In Press.
Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer 2009 Mar 1;124(5):1161-8. [Abstract]
Bentley TG, Weinstein MC, Willett WC, Kuntz KM. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr 2008;1:1-13. [Abstract]
Jeon J, Meza R, Moolgavkar SH, Luebeck EG. Evaluation of screening strategies for pre-malignant lesions using a biomathematical approach. Math Biosci 2008;213;56-70. [Abstract]
Miglioretti DL, Brown ER. A marginalized diffusion model for estimating age at first lower endoscopy use from current-status data. J R Stat Soc Ser C Appl Stat 2008;57(1):61-74. [Abstract]
Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care 2008;46(9 Suppl 1):S91-6. [Abstract]
Scherer R, Knudsen A, Pearson SD. Institute for Clinical and Economic Review. Final Appraisal Document. CT Colonography for Colorectal Cancer Screening. 2008 Jan. Available from: http://www.hta.hca.wa.gov/documents/ctc_final_evidence.pdf
Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008 Nov 4;149(9):659-69. Epub 2008 Oct 6. [Abstract]
Rutter CM, Yu O, Miglioretti DM. A hierarchical non-homogeneous Poisson model for meta-analysis of adenoma counts. Stat Med 2007;26:98-109. [Abstract]
Wang YC, Colditz GA, Kuntz KM. Forecasting the obesity epidemic in the aging U.S. population. Obesity 2007 Nov;15(11):2855-65. [Abstract]
Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007 Dec 20. Available from: https://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=52.
Bentley TG, Willett WC, Weinstein MC, Kuntz KM. Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health 2006 Nov;96(11):2040-7. [Abstract]
Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.: mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006 Aug 24;107(7):1624-33. [Abstract]
Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK, U.S. Multi-Society Task Force on Colorectal Cancer, American Cancer Society. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the U.S. Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology May 2006;130(6):1872-85. [Abstract]
Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the U.S. Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006;56(3):143-59; quiz 184-5. [Abstract]
de Visser M, van Ballegooijen M, Bloemers SM, van Deventer SJ, Jansen JB, Jespersen J, Kluft C, Meijer GA, Stoker J, de Valk GA, Verweij MF, Vlems FA. Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT. Cell Oncol 2005;27(1):17-29. [Abstract]
Knudsen AB. Explaining secular trends in colorectal cancer incidence and mortality with an empirically-calibrated microsimulation model [Ph.D. dissertation]. Cambridge, MA: Harvard University. 2005. [Abstract]
Loeve F, Boer R, Zauber AG, van Balleooijen M, van Oortmarssen GJ, Winawer SJ, Habbema JD. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004;111:633-9. [Abstract]
Loeve F, van Ballegooijen M, Boer R, Kuipers EJ, Habbema JDF. Colorectal cancer risk in adenoma patients: a nation-wide study. Int J Cancer 2004:111(1):147-41. [Abstract]
Schrag D. The price tag on progress-chemotherapy for colorectal cancer. New Eng J Med 2004;351(4):317-9. [Abstract]
van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. 2003 Aug. Available from: http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=20
Lung Working Group
Deng L, Kimmel M, Foy M, Spitz M, Wei Q and Gorlova O. Estimation of the effects of smoking and DNA-repair capacity on coefficients of the carcinogenesis model of lung cancer. Int J Cancer 2008 Nov 11. [Abstract]
Levy DT, Tworek C, Hahn EJ, Davis RE. The Kentucky SimSmoke tobacco policy simulation model: reaching Healthy People 2010 goals through policy change. South Med J 2008 May;101(5):503-7. [Abstract]
McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JO, Swensen SJ, Gazelle GS. Estimating long-term effectiveness of lung cancer screening in the Mayo CT Screening Study. Radiology 2008 Jul;248(1):278-87. [Abstract]
McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS. Forthcoming. Adopting helical CT screening for lung cancer: potential health consequences over a fifteen-year period. Cancer 2008 Dec 15;113(12):3440-9. [Abstract]
Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the nurses' health and the health professionals' follow-up studies using a multistage carcinogenesis model. Cancer Causes Control Apr 2008;19(3):317-28. [Abstract]
Levy DT. The role of public policies in reducing smoking prevalence: results from the SimSmoke tobacco policy simulation model. In: Bonnie RJ, Stratton K, Wallace RB, editors. Committee on Reducing Tobacco Use: Strategies, Barriers, and Consequences, Ending the Tobacco Problem: A Blueprint for the Nation. Washington, D.C.: Institute of Medicine. 2007. p. 578-598. [Full Text]
Levy DT, Hyland A, Higbee C, Remer L, Compton C. The role of public policies in reducing smoking prevalence in California: results from the California tobacco policy simulation model. Health Policy 2007 Jul;82(2):167-85. [Abstract]
Levy DT, Mumford EA, Gerlowski DA. Examining trends in quantity smoked. Nicotine Tob Res 2007 Dec;9(12):1287-96. [Abstract]
Levy DT, Ross H, Powell L, Bauer J, Lee HR. The role of public policies in reducing smoking prevalence in Arizona: results from the Arizona tobacco policy simulation model. J Public Health Manag Pract 2007 Jan-Feb;13(1):59-67. [Abstract]
Marciniak-Czochra A, Kimmel M. Modelling of early lung cancer progression: influence of growth factor production and cooperation between partially transformed cells. Math Models Methods Appl Sci 2007;17(Suppl):1693-719.
Holford TR. Approaches to fitting age-period-cohort models with unequal intervals. Stat Med 2006 Mar 30;25(6):997-93. [Abstract]
Levy DT, Bauer JE, Lee HR. Simulation modeling and tobacco control: creating more robust public health policies. Am J Public Health 2006 Mar;96(3):494-8. [Abstract]
Levy DT, Mumford EA, Compton C. Tobacco control policies and smoking in a population of low education women, 1992-2002. J Epidemiol Community Health 2006 Sep;60 Suppl 2:20-6. [Abstract]
Clements MS, Armstrong BK, Moolgavkar SH. Lung cancer rate predictions using generalized additive models. Biostat 2005 Oct;6(4):576-89. Epub 2005 Apr 28. [Abstract]
Gorlova O, Peng B, Yankelevitz D, Henschke C, Kimmel M. Estimating the growth rates of primary lung tumours from samples with missing measurements. Stat Med 2005 Apr 15;24(7):1117-34. [Abstract]
Hazelton WD, Clements MS, Moolgavkar SH. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev 2005 May;14(5):1171-81. [Abstract]
Kimmel M, Gorlova O and Henschke CI. Modeling lung cancer screening. Chapter 10, in: Edler L and Kitsos C, eds. Recent Advances in Quantitative Methods in Cancer and Human Health Risk Assessment. New York: Wiley; 2005. p. 161-76. [Summary]
Levy D, Mumford E, Cummings M, Gilpin B, Giovino G, Hyland A, Sweanor D, Warner K. The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: Estimates of a panel of experts. Addict Behav 2006 Jul;31(7):1190-200. Epub 2005 Oct 26. [Abstract]
Levy DT, Nikolayev L, Mumford EA. Recent trends in smoking and the role of public policies: results from the SimSmoke Tobacco Control Policy Simulation Model. Addiction 2005;10(10):1526-37. [Abstract]
Levy DT, Nikolayev L, Mumford EA, Compton C. The Healthy People 2010 smoking prevalence and tobacco control objectives: results from the SimSmoke tobacco control policy simulation model (United States). Cancer Causes Control 2005 May;16(4):359-71. [Abstract]
Feuer EJ, Boer R, Holford TR. Developing and comparing population models for the early detection of cancer. Stat Meth Med Res 2004 Dec;13:419-20.
Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, Warner KE. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004 Dec;13(12):2035-42. [Abstract]
Gorlova OY, Amos C, Henschke C, Lei L, Spitz M, Wei Q, Wu X, Kimmel M. Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. Hum Hered 2003;56:139-45. [Abstract]
Gregori G, Hanin LG, Luebeck G, Moolgavkar S, Yakovlev A. Testing goodness of fit for stochastic models of carcinogenesis. Math Biosci 2002 Jan;175(1):13-29. [Abstract]
Levy DT, Chaloupka F, Gitchell J, Mendez D, Warner KE. The use of simulation models for the surveillance, justification and understanding of tobacco control policies. Health Care Manag Sci Apr 2002;5(2):113-20. [Abstract]
Prostate Working Group
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Forthcoming. Reconciling differing estimates of lead time and overdiagnosis due to PSA screening: results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst In Press.
Etzioni R, Gulati R, Mariotto AB. 2009 Overview of prostate cancer trends in the era of PSA screening. In: Ankerst DP, Tangen CM, Thompson IM, editors. Prostate Cancer screening. 2nd ed. The Humana Press Inc. In Press.
Etzioni R, Feuer E. Studies of prostate-cancer mortality: caution advised. Lancet Oncol 2008 May;9(5):407-9. [Abstract]
Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the U.S.: a surveillance modeling approach. Med Decis Making 2008 Mar 4;28(3):323-31. [Abstract]
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, diTommaso D, Karnofski K, Gulati R, Penson DF, Feuer EJ. Quantifying the role of PSA screening in the U.S. prostate cancer mortality decline. Cancer Causes Control 2008 Mar;19(2):175-81. [Abstract]
Inoue LY, Etzioni R, Morrell C, Muller P. Modeling disease progression with longitudinal markers. J Am Stat Assoc 2008 Mar;103(481):259-70. [Abstract]
Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008 Mar;64(1):10-9. [Abstract]
Tsodikov A, Chefo S. Generalized sef-consistency: multinomial logit model and Poisson likelihood. J Stat Plan Inference 2008;138(8):2380-97. [Abstract]
Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the U.S. from Medicare claims and the National Health Interview Survey. Cancer 2007 Mar 19;109(9):1877-86. [Abstract]
Tsodikov A, Garibotti G. Profile information matrix for nonlinear transformation models. Lifetime Data Anal 2007 Mar;13(1):139-59. [Abstract]
Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care 2007 Feb; 45(2):154-9. [Abstract]
Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006 Nov 15;119(10):2366-71. [Abstract]
Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006 Aug 30;25(16):2846-66. [Abstract]
Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2006 Oct 1;66(2):395-402. [Abstract]
Broët P, Tsodikov A. De Rycke Y, Moreau T. Two-sample statistics for testing the equality of survival functions against improper semi-parametric accelerated failure time alternatives: An application to the analysis of a breast cancer clinical trial. Lifetime Data Anal 2004;10(2):103-20. [Abstract]
Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec;13(6):421-42. [Abstract]
Inoue LY, Etzioni R, Slate EH, Morrell C, Penson DF. Combining logitudinal studies of PSA. Biostat 2004;5:483-500. [Abstract]
Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 2004 Dec 1;160(11):1059-69. [Abstract]
Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004 Dec;64(6):1171-6. [Abstract]
Tsodikov A. Semiparametric models: a generalized self-consistency approach. J R Stat Soc Ser B Stat Methodol 2003 Aug;65(3):759-74. [Abstract]
Tsodikov AD, Ibrahim JG,Yakovlev AY. Estimating cure rates from survival data: an alternative to two-component mixture models. J Amer Statist Assoc 2003;98:1063-78. [Abstract]
Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni R. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 2003 Aug 1;98(3):496-503. [Abstract]
Etzioni R, Berry KM, Legler J, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991-1998. Urology 2002 Feb;59(2):251-255. [Abstract]
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 Jul 3;94(13):981-90. [Abstract]
McCulloch CE, Lin H, Slate EH, Turnbull BW. Discovering subpopulation structure with latent class mixed models. Stat Med 2002 Feb 15;21(3):417-29. [Abstract]
